Bayer AG : Bayer : Annual Peak Sales Potential of EUR5.5 Billion From 5 New Drugs
11/14/2012| 05:01am US/Eastern
By Friedrich Geiger
FRANKFURT--German pharmaceutical and chemical company Bayer AG (BAYN.XE) said Wednesday it sees peak annual sales potential of 5.5 billion euros ($7 billion) for its five new drugs Xarelto, Stivarga, Alpharadin, Aflibercept and Riociguat.
Bayer now includes the new drug Riociguat, which helps to treat pulmonary hypertension, in its sales forecast. The company said late last year that it sees peak sales potential of at least EUR1 billion for the cancer drugs Alpharadin and Regorafenib, also known as Stivarga, as well as the eye medicine Aflibercept, also known as Eylea and VEGF Trap-Eye.
Bayer Wednesday reiterated its estimate of a peak sales potential above EUR2 billion for the blood thinner Xarelto. The company has a total of 35 projects in clinical development.
Bayer's CropScience unit for agricultural chemicals sees a peak sales potential exceeding EUR4 billion for the products expected to be introduced between 2011 and 2016.
Natali Schwab contributed to this article.
Write to Friedrich Geiger at email@example.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires